Quest PharmaTech Names New CEO Jeffrey Shon
News related to:Quest PharmaTech Inc · 1 min read
EDMONTON, Alberta, Sept. 25, 2026 /CourierPR/ -- Quest PharmaTech Inc., a Canadian-based biopharmaceutical company, is set to undergo a leadership transition as it announces the retirement of its long-serving Chief Executive Officer, Dr. Madi Madiyalakan, effective November 23, 2026. Dr. Madiyalakan, who has been at the helm of the company since August 2006, will step down after 20 years of dedicated service. The company will be led by Mr. Jeffrey Shon, who currently serves as a director, taking over the role of CEO.
Mr. Shon, who brings extensive experience in legal, regulatory, and corporate affairs, including venture capital funding focused on emerging technologies, is poised to lead the company into its next phase of growth.
The annual and general shareholder meeting (AGM) will be held on the same day, November 23, 2026, at 3:00 pm in the company’s corporate offices in Edmonton. Notably, Dr. Madiyalakan will not be standing for re-election as a director at the AGM but will continue to consult with the company to ensure a smooth transition of operations.
Quest PharmaTech Inc. is developing products to improve the quality of life through its investments in companies and proprietary technologies. The company holds a 26.6% ownership interest in OQPBIOM Inc., a Korean company developing immunotherapeutic products for cancer treatment. Additionally, Quest has a 23% ownership interest in OncoVent, a Chinese joint venture focused on developing antibody-based immunotherapeutic products for cancer in the Greater China territory. The company is also in the late preclinical stage of developing its proprietary MAb AR 9.6, targeting truncated MUC16 as a theranostic agent for cancer.
This leadership change marks a significant milestone in Quest’s history, as the company transitions to a new chapter under Mr. Shon’s leadership. The future of the company is expected to be shaped by his expertise and vision, as the company continues to innovate and develop life-improving pharmaceutical solutions.